Skip to the main content

Review article

Pharmacogenomics in the treatment of acute lymphoblastic leukemia in children

Jelena Roganović ; Clinic for pediatrics, Clinical Hospital center Rijeka, Croatia

Full text: croatian pdf 577 Kb

page 16-21

downloads: 2.272



ABSTRACT. Over the past decades, the treatment of acute lymphoblastic leukemia in
children has made remarkable progress. Pharmacogenomics of acute leukemias elucidates
mechanisms of genetic control of antileukemic effects of chemotherapy and development
of drug resistance. The aim of pharmacogenomic studies, related to the treatment of
pediatric acute lymphoblastic leukemias, is to identify genes responsible for drug efficacy
and toxicity, matched with the genetic makeup of every individual child. Pharmacogenomics
offers the reasonable promise of therapeutic optimization and individualization, and further
improvement of treatment outcome in childhood lymphoblastic leukemia.


acute lymphoblastic leukemia, child, pharmacogenomics

Hrčak ID:



Article data in other languages: croatian

Visits: 2.937 *